No Data
US Stock MarketDetailed Quotes
ACCD Accolade
Watchlist
9.140
+0.080+0.88% Close 12/04 16:00 ET
9.1400.0000.00%
Post 16:20 ET
9.200High8.810Low616.81KVolume
9.020Open9.060Pre Close5.59MTurnover0.90%Turnover RatioLossP/E (TTM)696.76MMarket Cap17.00552wk HighLossP/E (Static)76.23MShares6.33052wk Low1.59P/B626.34MFloat Cap65.250Historical High--Dividend TTM68.53MShs Float4.610Historical Low--Div YieldTTM4.31%Amplitude9.058Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Accolade Company
Accolade, Inc. engages in the provision of personalized health and benefits solutions. Its products include Accolade Total Benefits, which is designed for employers with low employee adoption of healthcare and benefits programs; Accolade Total Care, which focuses on influencing the actual interactions between employees and providers, and are also interested in care management services; and Accolade Total Health and Benefits, which offers full suite of solutions. The company was founded by Thomas K. Spann, J. Michael Cline, and Sudhir Steven Singh in 2007 and is headquartered in Seattle, WA.
Revenue Breakdown
Business
Currency:USD
2023/02/28
Stock NameRevenueRatio
Single segment363.14M100.00%
News
Accolade To Present at Piper Sandler 35th Annual Healthcare Conference
SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Piper Sandler 35th Annual Healthcare
Expert Ratings for Accolade
Within the last quarter, Accolade (NASDAQ:ACCD) has observed the following analyst ratings: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings43000Last 30D010001M Ago000002M Ago420
Piper Sandler Maintains Overweight on Accolade, Lowers Price Target to $12
Piper Sandler analyst Jessica Tassan maintains Accolade (NASDAQ:ACCD) with a Overweight and lowers the price target from $15 to $12.
Comments
ColumnsToday's pre-market stock movers: KSS, NIO, MU, LULU and more
Gainers:
• $Cytokinetics(CYTK.US$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng(XPEV.US$ +3.4% (June deliveries)
• $NIO Inc(NIO.US$ +2.9% (June deliveries)
• $Bitfarms(BITF.US$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade(ACCD.US$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals(BCRX.US$ +2.6% (presents new data demonstrating...
• $Cytokinetics(CYTK.US$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng(XPEV.US$ +3.4% (June deliveries)
• $NIO Inc(NIO.US$ +2.9% (June deliveries)
• $Bitfarms(BITF.US$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade(ACCD.US$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals(BCRX.US$ +2.6% (presents new data demonstrating...
18
1
ColumnsTop upgrades and downgrades on 5/2
Upgrades
• $Accolade(ACCD.US$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $6 (from $9)
• $Comerica(CMA.US$ : Piper Sandler Upgrades to Overweight from Neutral - PT $94 (from $90)
• $New Oriental(EDU.US$ : JPMorgan Upgrades to Neutral from Underweight - PT $14 (from $35)
• $EPAM Systems(EPAM.US$ : Piper Sandler Upgrades to Overweight from Neutral - PT $348 (from $359)
• $Empire State Realty Trust Inc(ESRT.US$ : Evercore ISI Upgrades to Outp...
• $Accolade(ACCD.US$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $6 (from $9)
• $Comerica(CMA.US$ : Piper Sandler Upgrades to Overweight from Neutral - PT $94 (from $90)
• $New Oriental(EDU.US$ : JPMorgan Upgrades to Neutral from Underweight - PT $14 (from $35)
• $EPAM Systems(EPAM.US$ : Piper Sandler Upgrades to Overweight from Neutral - PT $348 (from $359)
• $Empire State Realty Trust Inc(ESRT.US$ : Evercore ISI Upgrades to Outp...
18
1
thank youColumnsToday's pre-market stock movers: AMZN, AAPL, MA, CVX and more
Gainers:
• $GTY Technology(GTYH.US$ +118.1% (entered into a definitive agreement to be acquired by GI Partners )
• $Finch Therapeutics(FNCH.US$ +68.33% (announces removal of FDA clinical hold on CP101 IND)
• $Zymeworks(ZYME.US$ +42.34% (confirms receipt of non-binding proposal from All Blue Falcons for $10.50 per share in cash)
• $Hub Group(HUBG.US$ +16.3% (earnings reports)
• $Lantheus(LNTH.US$ +14.2% (earnings reports)
• $Mohawk Industries(MHK.US$ +13.7% (e...
• $GTY Technology(GTYH.US$ +118.1% (entered into a definitive agreement to be acquired by GI Partners )
• $Finch Therapeutics(FNCH.US$ +68.33% (announces removal of FDA clinical hold on CP101 IND)
• $Zymeworks(ZYME.US$ +42.34% (confirms receipt of non-binding proposal from All Blue Falcons for $10.50 per share in cash)
• $Hub Group(HUBG.US$ +16.3% (earnings reports)
• $Lantheus(LNTH.US$ +14.2% (earnings reports)
• $Mohawk Industries(MHK.US$ +13.7% (e...
18
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
dingsterx : Ok